Prophylactic Anecortave Acetate in Patients With a Retisert Implant

Completed · Phase 1

Conditions studied: Uveitis, Posterior, Glaucoma

In brief

Retisert implant is an effective therapy for controlling inflammation in patients with non-infectious posterior uveitis. One of the major complications of this device is the development of elevated intraocular pressure (IOP) following implantation in 60% of patients. Glaucoma filtering is required in over 30% of patients at 2 years. Anecortave acetate (AA) has been shown to reduce steroid induced elevated IOP. The purpose of this study was to evaluate the ability of prophylactic anterior juxtascleral depot administration of AA to prevent this Retisert induced elevated IOP.

Key facts

Study ID
NCT00570479
Run by
Texas Retina Associates
People needed
12
Starts
2006-09-01
Expected to finish
2010-03-01
Last updated by the study team
2012-06-05

Who can join

Age: 10 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.